AstraZeneca's phase III trial results for tozorakimab in treating chronic obstructive pulmonary disease (COPD) showed significant reduction in flare-ups, especially in former smokers. The drug met its primary endpoint with a 29% to 34% reduction in exacerbations and showed stronger results in patients with high eosinophil counts compared to competitors. Citi values the drug's peak sales potential at $7 billion, nearly double the consensus estimate, and maintains a 'buy' rating on AstraZeneca stock. This optimistic outlook is supported by the drug's broad potential use across patient groups without the need for eosinophil testing.
Amgen's Phase 3 DeLLphi-305 study demonstrated that IMDELLTRA (tarlatamab-dlle) combined with AstraZeneca's durvalumab significantly improves overall survival, progression-free survival, and response rates compared to durvalumab alone in patients wit...
AstraZeneca released full data from two late-stage trials of its experimental COPD drug, tozorakimab, showing significant reduction in flare-ups among both former and current smokers. The drug, under FDA priority review with expected approval in earl...
AstraZeneca's drug Etcamah (camizestrant) received accelerated FDA approval for use with CDK4/6 inhibitors in hormone receptor positive, HER2 negative metastatic breast cancer patients with ESR1 mutations. This approval follows earlier European clear...
